BR112012030764A2 - métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin - Google Patents

métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin

Info

Publication number
BR112012030764A2
BR112012030764A2 BR112012030764A BR112012030764A BR112012030764A2 BR 112012030764 A2 BR112012030764 A2 BR 112012030764A2 BR 112012030764 A BR112012030764 A BR 112012030764A BR 112012030764 A BR112012030764 A BR 112012030764A BR 112012030764 A2 BR112012030764 A2 BR 112012030764A2
Authority
BR
Brazil
Prior art keywords
deazaanibopterin
methods
propargil
treating
methotrexate
Prior art date
Application number
BR112012030764A
Other languages
English (en)
Inventor
Gijsbertus J Pronk
Original Assignee
Allos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allos Therapeutics Inc filed Critical Allos Therapeutics Inc
Publication of BR112012030764A2 publication Critical patent/BR112012030764A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin. a presente invenção refere-se a um método para tratar um distúrbio metotrexato-resistente em um indivíduo, em que o método compreende a administração ao indivíduo de uma quantidade eficaz de 10-propangil-10-deazaaminopterin ou seus sais farmaceuticamente aceitáveis.
BR112012030764A 2010-06-02 2011-06-02 métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin BR112012030764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35087110P 2010-06-02 2010-06-02
PCT/US2011/038953 WO2011153368A1 (en) 2010-06-02 2011-06-02 Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin

Publications (1)

Publication Number Publication Date
BR112012030764A2 true BR112012030764A2 (pt) 2015-09-29

Family

ID=45067077

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030764A BR112012030764A2 (pt) 2010-06-02 2011-06-02 métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin

Country Status (16)

Country Link
US (1) US20130143891A1 (pt)
EP (1) EP2575466B1 (pt)
JP (1) JP5897558B2 (pt)
KR (1) KR20130115993A (pt)
CN (1) CN102984940B (pt)
AU (1) AU2011261384B2 (pt)
BR (1) BR112012030764A2 (pt)
CA (1) CA2800900A1 (pt)
DK (1) DK2575466T3 (pt)
ES (1) ES2541689T3 (pt)
HK (1) HK1179823A1 (pt)
IL (1) IL223078A (pt)
MX (1) MX339793B (pt)
RU (1) RU2586299C2 (pt)
WO (1) WO2011153368A1 (pt)
ZA (1) ZA201209673B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
CN102753175A (zh) 2010-02-02 2012-10-24 艾洛斯治疗学有限公司 10-炔丙基-10-去氮杂氨基蝶呤之光学纯非对映体以及使用所述非对映体的方法
RU2013102373A (ru) * 2010-08-10 2014-09-20 Аллос Терапьютикс, Инк. Продления выживаемости без прогрессирования заболевания с применением 10-пропаргил-10-деазааминоптерина
WO2013177713A1 (en) * 2012-05-31 2013-12-05 Alphora Research Inc. Process for preparation of an antifolate agent
WO2014020553A1 (en) * 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Salts of pralatrexate
CN104628727B (zh) * 2013-11-07 2018-08-21 正大天晴药业集团股份有限公司 一种普拉曲沙的晶型及其制备方法
CN104628728A (zh) * 2013-11-08 2015-05-20 深圳海王药业有限公司 一种普拉曲沙的制备方法
CN103588775B (zh) * 2013-11-12 2016-08-17 连云港恒运医药科技有限公司 普拉曲沙降解杂质及其制备方法
CN105272983B (zh) * 2014-06-12 2021-01-15 连云港润众制药有限公司 一种高纯度普拉曲沙固体及其制备方法
CN107488178B (zh) * 2016-06-10 2020-05-12 山东新时代药业有限公司 一种高纯度普拉曲沙中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
EP0638079B1 (en) * 1992-04-29 1999-12-15 Sri International Deazaaminopterins for treatment of inflammation
US6028071A (en) * 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
WO2005117891A1 (en) * 2004-05-30 2005-12-15 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Also Published As

Publication number Publication date
IL223078A (en) 2016-07-31
IL223078A0 (en) 2013-02-03
EP2575466A4 (en) 2013-07-17
MX339793B (es) 2016-06-10
EP2575466B1 (en) 2015-04-08
MX2012013740A (es) 2013-07-29
AU2011261384B2 (en) 2015-01-22
ES2541689T3 (es) 2015-07-23
WO2011153368A1 (en) 2011-12-08
ZA201209673B (en) 2014-03-26
CN102984940A (zh) 2013-03-20
JP5897558B2 (ja) 2016-03-30
US20130143891A1 (en) 2013-06-06
RU2586299C2 (ru) 2016-06-10
AU2011261384A1 (en) 2012-12-06
KR20130115993A (ko) 2013-10-22
JP2013527245A (ja) 2013-06-27
CN102984940B (zh) 2016-01-13
CA2800900A1 (en) 2011-12-08
DK2575466T3 (en) 2015-07-20
HK1179823A1 (en) 2013-10-11
EP2575466A1 (en) 2013-04-10
RU2012148767A (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
BR112012030764A2 (pt) métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
AU2019268066A1 (en) Methods of treating chronic disorders with complement inhibitors
PH12016500443A1 (en) Modulators of complement factor b
BR112015007061A2 (pt) composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente
BR112017024519A2 (pt) ?métodos para melhorar a neurocognição, para prevenir ou inibir a disfunção neurocognitiva e para proporcionar uma correção cruzada?
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
BR112015022390A2 (pt) método para o tratamento de doença de parkinson
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112014003801A2 (pt) composto, composição farmacêutica, e, métodos para a inibição de romk, para a provocação de diurese, natriurese ou ambas, e para o tratamento ou a profilaxia de um ou mais distúrbios
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112014030282A2 (pt) métodos de tratamento de excesso de peso e obesidade
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
BR112014002141A2 (pt) crizotinib para uso no tratamento de câncer
BR112014027303A2 (pt) identificação de variantes de isopreno sintase com propriedades optimizadas para a produção de isopreno
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112014021133A2 (pt) composto; composição farmacêutica; método para tratar, administrar e/ou reduzir as doenças ou distúrbios, síndrome ou afecções associados à modulação de receptor de captação de cálcio; e processo para a preparação de composto
WO2012166932A3 (en) Treating tear film disorders with mesenchymal stem cells
BR112017017071A2 (pt) nova lisina descarboxilase, e método para produzir cadaverina utilizando a mesma
BR112012008310A2 (pt) métodos para tratamento de tumores cerebrais
BR112014011223A2 (pt) método de tratar uma doença proliferativa
MX359930B (es) Uso de ácido siálico, precursor de ácido siálico o una combinación de los anteriores para preparar medicamentos útiles en una condición diabética o síndrome nefrótico.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.